Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.

H3N2 influenza viruses have now circulated in the human population for 43 years since the pandemic of 1968, accumulating sequence changes in the hemagglutinin (HA) and neuraminidase (NA) that are believed to be predominantly due to selection for escape from antibodies. Examination of mutations that...

Full description

Bibliographic Details
Main Authors: Lyubov Popova, Kenneth Smith, Ann H West, Patrick C Wilson, Judith A James, Linda F Thompson, Gillian M Air
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3405050?pdf=render
_version_ 1828743394874097664
author Lyubov Popova
Kenneth Smith
Ann H West
Patrick C Wilson
Judith A James
Linda F Thompson
Gillian M Air
author_facet Lyubov Popova
Kenneth Smith
Ann H West
Patrick C Wilson
Judith A James
Linda F Thompson
Gillian M Air
author_sort Lyubov Popova
collection DOAJ
description H3N2 influenza viruses have now circulated in the human population for 43 years since the pandemic of 1968, accumulating sequence changes in the hemagglutinin (HA) and neuraminidase (NA) that are believed to be predominantly due to selection for escape from antibodies. Examination of mutations that persist and accumulate led to identification of antigenically significant mutations that are contained in five antigenic sites (A-E) mapped on to the H3 HA. In early H3N2 isolates, antigenic site A appeared to be dominant while in the 1990s site B seemed more important. To obtain experimental evidence for dominance of antigenic sites on modern H3 HAs, we have measured antibodies in plasma of human subjects who received the 2006-07 trivalent subunit influenza vaccine (H3 component A/Wisconsin/67/05) or the 2008-09 formulation (H3 component A/Uruguay/716/07). Plasmas were tested against expressed HA of Wisconsin-like influenza A/Oklahoma/309/06 and site-directed mutants in antigenic site A (NNES121-124ITEG, N126T, N133D, TSSS135-138GSNA, K140I, RSNNS142-146PGSG), and antigenic site B (HL156-157KS, KFK158-160GST, NDQI189-192QEQT, A196V). "Native ELISA" analysis and escape mutant selection with two human monoclonal antibodies demonstrated that antibody E05 binds to antigenic site A and 1_C02 binds to site B. We find that most individuals, after vaccination in seasons 2006-07 and/or 2008-09, showed dominance of antigenic site B recognition over antigenic site A. A minority showed dominance of site A in 2006 but these were reduced in 2008 when the vaccine virus had a site A mutation. A better understanding of immunodominance may allow prediction of future antigenic drift and assist in vaccine strain selection.
first_indexed 2024-04-13T01:36:25Z
format Article
id doaj.art-687d6b4ccf9a4fffb3f77611d9c41c22
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-13T01:36:25Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-687d6b4ccf9a4fffb3f77611d9c41c222022-12-22T03:08:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4189510.1371/journal.pone.0041895Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.Lyubov PopovaKenneth SmithAnn H WestPatrick C WilsonJudith A JamesLinda F ThompsonGillian M AirH3N2 influenza viruses have now circulated in the human population for 43 years since the pandemic of 1968, accumulating sequence changes in the hemagglutinin (HA) and neuraminidase (NA) that are believed to be predominantly due to selection for escape from antibodies. Examination of mutations that persist and accumulate led to identification of antigenically significant mutations that are contained in five antigenic sites (A-E) mapped on to the H3 HA. In early H3N2 isolates, antigenic site A appeared to be dominant while in the 1990s site B seemed more important. To obtain experimental evidence for dominance of antigenic sites on modern H3 HAs, we have measured antibodies in plasma of human subjects who received the 2006-07 trivalent subunit influenza vaccine (H3 component A/Wisconsin/67/05) or the 2008-09 formulation (H3 component A/Uruguay/716/07). Plasmas were tested against expressed HA of Wisconsin-like influenza A/Oklahoma/309/06 and site-directed mutants in antigenic site A (NNES121-124ITEG, N126T, N133D, TSSS135-138GSNA, K140I, RSNNS142-146PGSG), and antigenic site B (HL156-157KS, KFK158-160GST, NDQI189-192QEQT, A196V). "Native ELISA" analysis and escape mutant selection with two human monoclonal antibodies demonstrated that antibody E05 binds to antigenic site A and 1_C02 binds to site B. We find that most individuals, after vaccination in seasons 2006-07 and/or 2008-09, showed dominance of antigenic site B recognition over antigenic site A. A minority showed dominance of site A in 2006 but these were reduced in 2008 when the vaccine virus had a site A mutation. A better understanding of immunodominance may allow prediction of future antigenic drift and assist in vaccine strain selection.http://europepmc.org/articles/PMC3405050?pdf=render
spellingShingle Lyubov Popova
Kenneth Smith
Ann H West
Patrick C Wilson
Judith A James
Linda F Thompson
Gillian M Air
Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.
PLoS ONE
title Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.
title_full Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.
title_fullStr Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.
title_full_unstemmed Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.
title_short Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.
title_sort immunodominance of antigenic site b over site a of hemagglutinin of recent h3n2 influenza viruses
url http://europepmc.org/articles/PMC3405050?pdf=render
work_keys_str_mv AT lyubovpopova immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses
AT kennethsmith immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses
AT annhwest immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses
AT patrickcwilson immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses
AT judithajames immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses
AT lindafthompson immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses
AT gillianmair immunodominanceofantigenicsiteboversiteaofhemagglutininofrecenth3n2influenzaviruses